ChemoCentryx Inc

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates in clinical development include CCX140 that has completed a Phase II clinical trial for the treatment of patients with diabetic…More nephropathy, a form of kidney disease; CCX872, an orally administered inhibitor that is under Phase Ib clinical trial for pancreatic cancer; and CCX168, which has completed a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic anti-body associated renal vasculitis.